Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | ||
| Sovaldi | Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete | ||
| Adempas | Riociguat | Chronic thromboembolic pulmonary hypertension | List with criteria/condition | Complete | ||
| Simponi I.V. | Golimumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
| Trisenox | Arsenic Trioxide | Acute Promyelocytic Leukemia | Reimburse | Complete | ||
| Aubagio | Teriflunomide | Multiple sclerosis, relapsing-remitting | Do not list at the submitted price | Complete | ||
| Intuniv XR | Guanfacine hydrochloride | Attention-deficit/hyperactivity disorder (ADHD) | Do not list | Complete | ||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, type 2 | List with criteria/condition | Complete | ||
| Galexos | Simeprevir | Hepatitis C, chronic | List with criteria/condition | Complete |
Last Updated : May 19, 2024